Open Access

Inhibition of human oral squamous cell carcinoma proliferation and migration by prodrug‑activating suicide gene therapies

  • Authors:
    • Naining Xu
    • Honglei Tian
    • Chun Po Fung
    • Yuntao Lin
    • Yuling Chen
    • Guang Zhu
    • Yuehong Shen
    • Chuanbin Guo
    • Hongyu Yang
  • View Affiliations

  • Published online on: January 9, 2023     https://doi.org/10.3892/etm.2023.11790
  • Article Number: 92
  • Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Head and neck squamous cell carcinoma (HNSCC), which originates from mucosal epithelium in the oral cavity, pharynx and larynx, is the sixth most common malignancy in the world. The prognosis of HNSCC is not satisfactory due to metastasis, resulting in 5‑year survival rates ranging from 65.9 to 67.2%. Previously, we developed a method to evaluate the effect prodrug‑activating suicide gene (PA‑SG) therapy on the proliferation of HNSCC. The present study investigated PA‑SG therapy on metastatic HNSCC by wound‑healing assay and our previously established method. HSC‑3 cells with stable expression of suicide genes thymidine kinase (TK) or cytosine deaminase (CD) were treated with prodrugs ganciclovir (GCV) or 5‑fluorocytosine (5‑FC), respectively. Both GCV and 5‑FC inhibited HSC‑3 proliferation while the bystander effect of CD/5‑FC was greater compared with that of TK/GCV. GCV showed a greater anti‑migration effect compared with that of 5‑FC. To the best of our knowledge, the present study is the first to evaluate the anti‑migratory and anti‑proliferative effects of PA‑SG therapies on metastatic HNSCC. This may also serve as a general method to quantify other types of PA‑SC therapy. The present results demonstrated that PA‑SG therapy is a promising treatment for anti‑metastatic HNSCC therapy development.

Related Articles

Journal Cover

February-2023
Volume 25 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xu N, Tian H, Fung CP, Lin Y, Chen Y, Zhu G, Shen Y, Guo C and Yang H: Inhibition of human oral squamous cell carcinoma proliferation and migration by prodrug‑activating suicide gene therapies. Exp Ther Med 25: 92, 2023
APA
Xu, N., Tian, H., Fung, C.P., Lin, Y., Chen, Y., Zhu, G. ... Yang, H. (2023). Inhibition of human oral squamous cell carcinoma proliferation and migration by prodrug‑activating suicide gene therapies. Experimental and Therapeutic Medicine, 25, 92. https://doi.org/10.3892/etm.2023.11790
MLA
Xu, N., Tian, H., Fung, C. P., Lin, Y., Chen, Y., Zhu, G., Shen, Y., Guo, C., Yang, H."Inhibition of human oral squamous cell carcinoma proliferation and migration by prodrug‑activating suicide gene therapies". Experimental and Therapeutic Medicine 25.2 (2023): 92.
Chicago
Xu, N., Tian, H., Fung, C. P., Lin, Y., Chen, Y., Zhu, G., Shen, Y., Guo, C., Yang, H."Inhibition of human oral squamous cell carcinoma proliferation and migration by prodrug‑activating suicide gene therapies". Experimental and Therapeutic Medicine 25, no. 2 (2023): 92. https://doi.org/10.3892/etm.2023.11790